BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/2/2026 8:37:17 AM | Browse: 3 | Download: 1
 |
Received |
|
2025-09-10 07:14 |
|
Peer-Review Started |
|
2025-09-10 07:16 |
|
First Decision by Editorial Office Director |
|
2025-10-18 02:38 |
|
Return for Revision |
|
2025-10-18 02:38 |
|
Revised |
|
2025-10-31 12:01 |
|
Publication Fee Transferred |
|
2025-11-10 03:59 |
|
Second Decision by Editor |
|
2025-12-16 02:39 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-12-16 07:10 |
|
Articles in Press |
|
2025-12-16 07:10 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-02-13 02:25 |
|
Publish the Manuscript Online |
|
2026-03-02 08:37 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Pristimerin ameliorates spasmolytic polypeptide-expressing metaplasia by modulating Cdkn1c (p57)-mediated glycolytic reprogramming
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jun-Song Wen, Zi-Wei Pan, Xue-Dan Yao, Yan-Qing Liu and Yao-Dong Zhu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
No. 82274355 |
| Key Project for the Cultivation of Outstanding Young Teachers in Anhui Province’s Colleges and Universities |
No. 2023-385 |
|
| Corresponding Author |
Yao-Dong Zhu, Chief Physician, Doctorate Student, Professor, Department of Integrated Traditional Chinese and Western Medicine Oncology, First Affiliated Hospital of Anhui Medical University, No. 120 Wanshui Road, High-tech Zone, Hefei 230000, Anhui Province, China. zhuyaodong2022@126.com |
| Key Words |
Pristimerin; Spasmolytic polypeptide-expressing metaplasia; Glycolytic reprogramming; Cdkn1c; Gastric organoids; Gastric precancerous lesion |
| Core Tip |
This study systematically investigated the therapeutic effects of the natural compound pristimerin on spasmolytic polypeptide-expressing metaplasia (SPEM) using a high-dose tamoxifen-induced mouse model, tamoxifen-treated human gastric epithelial cells, and N-methyl-N’-nitro-N-nitrosoguanidine/Helicobacter pylori-induced gastric organoids. It elucidated the underlying mechanism by which pristimerin ameliorates SPEM through regulating Cdkn1c (p57) to suppress glycolytic reprogramming. These findings not only provide novel mechanistic insights into pristimerin treatment for SPEM but also offer a crucial theoretical basis for targeting p57 in SPEM therapy. |
| Publish Date |
2026-03-02 08:37 |
| Citation |
Wen JS, Pan ZW, Yao XD, Liu YQ, Zhu YD. Pristimerin ameliorates spasmolytic polypeptide-expressing metaplasia by modulating Cdkn1c (p57)-mediated glycolytic reprogramming. World J Gastroenterol 2026; 32(10): 113771 |
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i10/113771.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v32.i10.113771 |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
